11:00 PM
 | 
Feb 27, 2018
 |  BioCentury  |  Finance

Repairing resistance

Why Novo Holdings launched fund to invest in antimicrobial resistance plays

While Novo Nordisk Foundation has funded antimicrobial resistance research for years, the foundation’s investment arm, Novo Holdings A/S, is taking that mandate a step further with its first fund dedicated to early stage venture in the space.

On Wednesday, Novo Holdings’ early venture group Novo Seeds launched the REPAIR Impact Fund with $165 million to invest in biotechs developing therapies for antimicrobial resistance.

According to Novo Seeds’ Søren Møller, the foundation has awarded about $35 million in grants over the past two years to combat...

Read the full 411 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >